The Vanguard Group 13D and 13G filings for Syndax Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-27 1:15 pm Sale | 2026-03-13 | 13G | SYNDAX PHARMACEUTICALS INC SNDX | The Vanguard Group | 0 0.000% | -6,230,334 (Position Closed) | Filing |
| 2026-01-30 2:43 pm Purchase | 2025-12-31 | 13G | SYNDAX PHARMACEUTICALS INC SNDX | The Vanguard Group | 6,230,334 7.160% | 1,894,981 (+43.71%) | Filing |
| 2024-02-13 5:15 pm Purchase | 2023-12-29 | 13G | SYNDAX PHARMACEUTICALS INC SNDX | The Vanguard Group | 4,335,353 5.110% | 4,335,353 (New Position) | Filing |